<DOC>
	<DOCNO>NCT00938366</DOCNO>
	<brief_summary>The purpose study assess influence pantoprazole pharmacokinetic profile cladribine , especially term extent absorption cladribine since pH-modifying drug may potentially affect stability cladribine thereby bioavailability</brief_summary>
	<brief_title>Drug-Drug Interaction Cladribine Pantoprazole Multiple Sclerosis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Subjects body mass index less equal ( &lt; = ) 28 body weight great ( &gt; ) 60 kilogram ( kg ) less ( &lt; ) 120 kg , screen Able understand inform consent give write , informed consent Had diagnosis clinically stable definite multiple sclerosis ( MS ) either McDonald Poser criterion Expanded disability status scale ( EDSS ) score exceed 5.0 Male nonpregnant , nonbreast feed woman age 18 65 year , inclusive time inform consent obtain Female subject lack childbearing potential define postmenopausal least two year , surgically medically sterile sexually inactive ; willing avoid pregnancy use adequate method birth control 28 day prior , 90 day last administration trial medication Other protocol define inclusion criterion could apply . Subjects present severe unstable disorder : poorly control diabetes arterial hypertension , severe cardiac insufficiency , unstable ischemic heart disease , significant preexist hematological disease , medical condition , opinion investigator , would constitute risk contraindication participation subject study could interfere study objective , conduct evaluation Subjects MS treatment ; subject nonstable symptomatic MS treatment ( stable dose define 3 week longer prior first study dose ) Clinically significant abnormal laboratory test result electrocardiogram findings opinion investigator could increase safety risk subject Positive result serology examination Hepatitis B surface antigen ( HbsAg ) due vaccination , hepatitis B core antibody ( HbcAb ) , Hepatitis C virus antibody ( antiHCV ) Human Immunodeficiency antibody ( antiHIV ) Signs symptom Transmissible Spongiform Encephalopathy screening , family member suffer Presence chronic recurrent infection acute infection within last 2 week first dose study period Presence gastrointestinal disease , opinion investigator , could affect pharmacokinetic outcome study Consumption concomitant medication could directly influence gastric acidity ( example : use antacid , histamine receptor ( H2 ) antagonists proton pump inhibitor ) take within 7 day study day 1 throughout study period Intake alcoholic beverage , caffeine caffeine containing beverage , grapefruit , orange , cranberry juice three fruit smoke 48 hour prior first dose 48 hour post dose ( cladribine ) Exposure investigational drug use investigational device 12 week prior first dose Intake medication could directly influence gastrointestinal motility absorption cladribine ( example , use H2antagonists , proton pump inhibitor ) 7 day prior cladribine administration Any immunomodulatory therapy ( include limit glatiramer acetate , interferon , natalizumab ) treatment oral systemic corticosteroid adrenocorticotropic hormone within 28 day first dose Any cytokine anticytokine therapy , IV immunoglobulin administration plasmapheresis prohibit 3 month prior first dose Current history presence drug alcohol abuse , confirm positive test result drug abuse and/or alcohol history drug alcohol abuse . Alcohol abuse define : average daily intake 3 unit weekly intake 21 male 14 unit female 1 unit equal 810 gram alcohol ( 1 unit equal 340 milliliter [ mL ] beer , 115 mL wine 43 mL spirit ) History presence hypertension significant cardiovascular abnormality , history heart kidney disease Current diagnosis personal history cancer Smoke 10 cigarette per day equivalent Loss donation 400 mL blood 12 week prior first dose . Definite suspect personal history family history adverse drug reaction hypersensitivity drug similar chemical structure cladribine pantoprazole know hypersensitivity cladribine pantoprazole excipients Presence history serious allergy ( require hospitalization prolong systemic treatment ) Pregnant nursing woman . Treatment pregnant nursing woman cladribine study prohibit Signs symptom neurological disease MS could explain symptom subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>